CriticalSystemic antimycotics. Imidazole derivatives×HMG-CoA reductase inhibitor (statin)
Updated · Methodology
Mechanism
The liver enzyme CYP3A4 clears lovastatin (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and ketoconazole strongly inhibits this enzyme (ketoconazole SmPC, European Medicines Agency, EMA). Itraconazole 200 mg daily raised lovastatin exposure (area under the curve, AUC) more than 36-fold and that of its active acid form 22-fold. According to the US Food and Drug Administration (FDA) lovastatin label, this result may also reflect other strong CYP3A4 inhibitors, including ketoconazole. Higher lovastatin levels raise the risk of muscle damage (myopathy) and muscle breakdown (rhabdomyolysis) (lovastatin SmPC, AEMPS). The higher the ketoconazole dose and the more often it is taken, the stronger the interaction, and the daily dose in Cushing's syndrome is 400–1200 mg (ketoconazole SmPC, EMA).
Symptoms
Myopathy causes muscle pain, tenderness or weakness, with creatine kinase (CK) above ten times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In rhabdomyolysis, myoglobin from damaged muscle passes into the urine and can cause acute kidney failure, rarely fatal (lovastatin SmPC, AEMPS). Warning signs are unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated in the lovastatin summary of product characteristics (SmPC) of the Spanish Agency of Medicines and Medical Devices (AEMPS), in the ketoconazole SmPC of the European Medicines Agency (EMA) and in the US Food and Drug Administration (FDA) labels of both drugs. If ketoconazole cannot be avoided, stop lovastatin for the whole course (lovastatin SmPC, AEMPS; lovastatin FDA label) and do not restart it until one week after the last ketoconazole dose (ketoconazole FDA label). Atorvastatin and simvastatin are also contraindicated with ketoconazole. CYP3A4 does not metabolise pravastatin or fluvastatin, so either can be taken with ketoconazole, and ketoconazole did not change rosuvastatin pharmacokinetics (ketoconazole SmPC, EMA). Before starting ketoconazole, review every medicine the patient takes (ketoconazole SmPC, EMA). Explain to the patient which medicines must not be taken with lovastatin, and ask them to report unexplained muscle pain, tenderness or weakness at once (lovastatin FDA label). If the patient has already taken both drugs and develops muscle pain, weakness or cramps, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal or myopathy is suspected (lovastatin SmPC, AEMPS). The contraindication applies to oral ketoconazole: in the European Union, ketoconazole tablets are used for endogenous Cushing's syndrome (ketoconazole SmPC, EMA). In adults, ketoconazole was not found in plasma after use of the cream on the skin or the gel on the scalp, but it was detected after use of the gel on the whole body (ketoconazole cream and gel SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ketoconazole Tablets USP 200 mg prescribing information (2026)– FDA label, DailyMed setid 1d598696-c6f3-4b7c-ad73-949d2089df35, revised 08/2026, Contraindications
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Lovastatina (nº registro 63360), sección 4.3 (2023)– AEMPS, CIMA, nº registro 63360 (Lovastatina Cinfa 20 mg, Laboratorios Cinfa), documento 05/2023 (texto revisado 05/2023), secciones 4.3, 4.4 y 4.5; texto idéntico en Lovastatina Cinfa 40 mg (nº registro 63359)
- FDA: Lovastatin Tablets USP (lovastatin) prescribing information (2026)– FDA, DailyMed setid df7ddf4f-d569-431e-81f1-9129d7043150 (Lupin Pharmaceuticals), revisión 05/2026 (versión 17), Clinical Pharmacology (tabla I), Contraindications, Warnings (Myopathy/Rhabdomyolysis) y Precautions
- AEMPS: Ficha técnica: Fungarest 20 mg/g crema (ketoconazol) (nº registro 57595), sección 5.2 (2023)– AEMPS, CIMA, nº registro 57595 (Fungarest 20 mg/g crema, Stada), documento 04/2023 (texto revisado 06/2021), secciones 4.5 y 5.2 (sin concentraciones plasmáticas cuantificables tras uso en la piel de adultos)
- AEMPS: Ficha técnica: Ketoconazol Sandoz 20 mg/g gel (nº registro 66037), sección 5.2 (2023)– AEMPS, CIMA, nº registro 66037 (Sandoz), documento 11/2023 (texto revisado 12/2021), secciones 4.5 y 5.2 (niveles plasmáticos detectados tras aplicación en todo el cuerpo)